ZBIOZenas BioPharma, Inc.

1. Aug 13, 2026Appointment of Christy J. Oliger Upon the recommendation of the Nominating and Corporate Governance Committee of the Company’s Board of Directors (the “Board”), on August 12, 2026, the Board appointed Christy J. Oliger to serve on the Board as a Class II director to hold office until the Company’s annual meeting of …Earnings release · Form 8-K
2. May 13, 2026On May 11, 2026, Zenas BioPharma, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”)Earnings release · Form 8-K
3. Mar 31, 2026On March 31, 2026, Zenas BioPharma, Inc. (the “Company”) completed its public offering (the “Convertible Notes Offering”) of $200,000,000 aggregate principal amount of its 2.50% Convertible Senior Notes due 2032 (the “Notes”)Material agreement entered · Form 8-K
4. Mar 16, 2026Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update.Earnings release · press release
5. Feb 13, 2026On February 10, 2026, the Board of Directors (the “Board”) of Zenas BioPharma, Inc. (the “Company”) approved the Company’s Amended and Restated Short-Term Incentive Plan (the “STI Plan”), effective as of January 1, 2026.Director or officer change · Form 8-K
6. Jan 5, 2026On January 5, 2026, the Company announced positive results from the INDIGO trial. The INDIGO trial enrolled a total of 194 patients, randomized to obexelimab (n=97) and placebo (n=97)Earnings release · Form 8-K
7. Dec 15, 2025Adoption of Inducement Plan On December 10, 2025, the Board approved the Zenas BioPharma, Inc. 2026 Inducement Plan (the “2026 Inducement Plan”), the form of Non-Statutory Stock Option Agreement under the 2026 Inducement Plan (the “Form Inducement Option Agreement”), the form of Global Non-Statutory Stock Option …Director or officer change · Form 8-K
8. Nov 12, 2025Zenas BioPharma Reports Third Quarter 2025 Financial.Earnings release · press release
9. Oct 27, 2025On October 27, 2025, the Company announced positive results from the MoonStone trial of obexelimab in RMS. Obexelimab met the primary endpoint, demonstrating a statistically significant 95% relative reduction in the cumulative number of new gadolinium (“Gd”)-enhancing (“GdE”) T1 hyperintense lesions, which are markers …Regulation FD disclosure · Form 8-K
10. Oct 8, 2025On October 7, 2025, Zenas BioPharma, Inc. (“Zenas” or the “Company”) entered into a License Agreement (the “InnoCare License Agreement”) with InnoCare Pharma Inc. (“InnoCare”)Material agreement entered · Form 8-K

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.